A 6-month, open-label study of memantine in patients with frontotemporal dementia

International Journal of Geriatric Psychiatry
Janine Diehl-SchmidAlexander Kurz

Abstract

To evaluate safety and effects on cognition and behavior of memantine 20 mg/day in the treatment of patients with frontotemporal dementia (FTD). This was a single-center, 6-month, open, uncontrolled study. Sixteen outpatients with a diagnosis of FTD were enrolled. On the CIBIC plus 26 weeks after baseline four of the 16 patients were minimally improved, four were unchanged, seven were minimally worse and one patient was moderately worse. Neither the Neuropsychiatric Inventory nor the Frontal Behavioral Inventory demonstrated statistically significant differences in behavior between baseline and final visit. There was an increase in the total Alzheimer's Disease Assessment Scale score, reflecting a decline in cognitive performance. Executive functions as well as activities of daily living and extrapyramidal motor symptoms (EPMS) remained unchanged during the trial. The number of patients was small, so that the evidence given by statistical tests is limited. Thus, the present study can only show trends regarding drug effects. As memantine is well-tolerated, further randomized and controlled studies should be conducted to evaluate drug efficacy.

References

Nov 1, 1975·Journal of Psychiatric Research·M F FolsteinP R McHugh
Jun 1, 1987·Seminars in Neurology·S Fahn
Feb 1, 1997·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·A KerteszH Fox
Aug 26, 1998·Dementia and Geriatric Cognitive Disorders·I HindmarchH Erzigkeit
Aug 7, 1999·Dementia and Geriatric Cognitive Disorders·D Neary
Aug 7, 1999·Dementia and Geriatric Cognitive Disorders·I Ferrer
Aug 7, 1999·Dementia and Geriatric Cognitive Disorders·A W ProcterP T Francis
Dec 13, 2000·Neurology·B DuboisB Pillon
Oct 24, 2002·American Journal of Alzheimer's Disease and Other Dementias·Tiffany W Chow, Mario F Mendez
Aug 13, 2003·Neurology·J R HodgesG Halliday
Sep 6, 2003·American Journal of Alzheimer's Disease and Other Dementias·Rita MorettiAntonio Bava
Jun 5, 2004·Dementia and Geriatric Cognitive Disorders·Florence PasquierFlorence Lebert
Jun 5, 2004·Dementia and Geriatric Cognitive Disorders·Florence LebertFlorence Pasquier
Nov 24, 2004·Drugs & Aging·Rita MorettiAntonio Bava
Apr 27, 2005·Neurology·W W SeeleyH J Rosen
Jul 25, 2006·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·Elaine R PeskindScott McDonald
Sep 15, 2006·Fortschritte der Neurologie-Psychiatrie·J Diehl-SchmidA Kurz
Jun 5, 2007·Alzheimer Disease and Associated Disorders·Margaret M Swanberg

❮ Previous
Next ❯

Citations

Aug 26, 2009·Der Nervenarzt·J Diehl-SchmidA Danek
Aug 2, 2011·Der Nervenarzt·M OttoUNKNOWN FTLD consortium
Mar 4, 2009·European Archives of Psychiatry and Clinical Neuroscience·Robert PerneczkyJanine Diehl-Schmid
Aug 1, 2012·Current Neurology and Neuroscience Reports·Masood Manoochehri, Edward D Huey
Feb 7, 2012·Current Treatment Options in Neurology·Tarik KarakayaHarald Hampel
May 26, 2011·Journal of Molecular Neuroscience : MN·Ezequiel GleichgerrchtFacundo Manes
Sep 23, 2010·Neurocase·Edward C LauterbachLauren L Greenway
Jan 13, 2010·The Neurologist·Zoe Arvanitakis
Oct 9, 2009·Alzheimer Disease and Associated Disorders·Adam L BoxerBruce L Miller
Jun 28, 2011·Alzheimer Disease and Associated Disorders·Janine Diehl-SchmidAlexander Kurz
Nov 8, 2008·Current Opinion in Neurology·Keith A Vossel, Bruce L Miller
Feb 4, 2010·American Journal of Alzheimer's Disease and Other Dementias· Bei HuAdam L Boxer
Aug 1, 2010·Continuum : Lifelong Learning in Neurology·William T Hu
Oct 24, 2009·Clinical Interventions in Aging·Stuart J Thomas, George T Grossberg
Jul 28, 2011·Neuropsychiatric Disease and Treatment·Tiffany W ChowBruce G Pollock
Sep 7, 2012·CNS Drugs·Rachel E Seltman, Brandy R Matthews
Jan 29, 2014·Current Treatment Options in Neurology·Melissa J Armstrong
Sep 3, 2013·Neurodegenerative Disease Management·Mandana ModirroustaBradford C Dickerson
May 8, 2013·Neurología : publicación oficial de la Sociedad Española de Neurología·M Fernández-MatarrubiaJ Matías-Guiu
Sep 23, 2014·Current Treatment Options in Neurology·Richard M Tsai, Adam L Boxer
Oct 15, 2008·Expert Opinion on Therapeutic Targets·Edward D HueyJordan Grafman
Oct 1, 2011·Expert Review of Neurotherapeutics·Daphne Lo, George T Grossberg
Feb 25, 2009·Expert Opinion on Drug Safety·Harish Kavirajan
Aug 16, 2011·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·Karen BermanKatrin Seeher
Jun 16, 2009·Behavioural Brain Research·Susanne NikolausHans-Wilhelm Müller
Jun 8, 2012·International Journal of Geriatric Psychiatry·Tiffany W ChowBruce G Pollock
Jul 21, 2009·Biochimica Et Biophysica Acta·Heng Du, Shirley ShiDu Yan
Feb 24, 2015·The Medical Clinics of North America·Kerry L Hildreth, Skotti Church
May 5, 2016·International Journal of Law and Psychiatry·Jutta Maria BirkhoffLaura Re
Mar 30, 2017·Journal of Geriatric Psychiatry and Neurology·Massimiliano BuoliAlfredo Carlo Altamura
May 4, 2011·Revista brasileira de psiquiatria : orgão oficial da Associação Brasileira de Psiquiatria, Asociación Psiquiátrica de la América Latina·Maria da Glória PortugalJerson Laks
Dec 12, 2012·American Journal of Alzheimer's Disease and Other Dementias·Xinling WangWei Chen
Nov 20, 2010·Journal of Psychopharmacology·John T O'BrienUNKNOWN BAP Dementia Consensus Group
Oct 30, 2013·American Journal of Alzheimer's Disease and Other Dementias·Maria Nardell, Rajesh R Tampi
Sep 30, 2017·Archives of Clinical Neuropsychology : the Official Journal of the National Academy of Neuropsychologists·Adam Gerstenecker
Jun 5, 2018·Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·A S AvedisovaR G Akzhigitov
Sep 15, 2010·International Psychogeriatrics·Janine Diehl-SchmidThomas Jahn
Mar 7, 2020·Cognitive and Behavioral Neurology : Official Journal of the Society for Behavioral and Cognitive Neurology·Calvin TrieuAnnemieke Dols
Mar 10, 2011·Expert Opinion on Pharmacotherapy·Nathan HerrmannKrista Lanctôt
Mar 21, 2019·The Cochrane Database of Systematic Reviews·Rupert McShaneJean Debarros
Jul 6, 2011·Expert Review of Neurotherapeutics·Geoffrey A KerchnerAdam Boxer

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.